These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35109867)

  • 1. Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy.
    Chen H; Zhang P; Shi Y; Liu C; Zhou Q; Zeng Y; Cheng H; Dai Q; Gao X; Wang X; Liu G
    J Nanobiotechnology; 2022 Feb; 20(1):61. PubMed ID: 35109867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for "cold" tumor immunotherapy.
    Zhang X; Yi C; Zhang L; Zhu X; He Y; Lu H; Li Y; Tang Y; Zhao W; Chen G; Wang C; Huang S; Ouyang G; Yu D
    Acta Biomater; 2023 Mar; 159():338-352. PubMed ID: 36669551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically engineered PD-1 displaying nanovesicles for synergistic checkpoint blockades and chemo-metabolic therapy against non-small cell lung cancer.
    Li B; Yang T; Liu J; Yu X; Li X; Qin F; Zheng J; Liang J; Zeng Y; Zhou Z; Liu L; Zhang B; Yao W; Feng Z; Zeng G; Zhou Q; Chen L
    Acta Biomater; 2023 Apr; 161():184-200. PubMed ID: 36893957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
    Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
    Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision USPIO-PEG-SLe
    Li T; Guo L; Li J; Mu X; Liu L; Song S; Luo N; Zhang Q; Zheng B; Jin G
    Int J Nanomedicine; 2024; 19():1249-1272. PubMed ID: 38348177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically Programmable Vesicles for Enhancing CAR-T Therapy against Solid Tumors.
    Li X; Zhu T; Wang R; Chen J; Tang L; Huo W; Huang X; Cao Q
    Adv Mater; 2023 May; 35(19):e2211138. PubMed ID: 36814099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy.
    Xu X; Liu L; Wang H; Li W; Zou Y; Zeng Y; Yang Q; Bai D; Dai D
    ACS Biomater Sci Eng; 2022 Nov; 8(11):4819-4826. PubMed ID: 36206367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy.
    Zhang X; Wang C; Wang J; Hu Q; Langworthy B; Ye Y; Sun W; Lin J; Wang T; Fine J; Cheng H; Dotti G; Huang P; Gu Z
    Adv Mater; 2018 May; 30(22):e1707112. PubMed ID: 29656492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photothermal-Activatable Fe
    Ge R; Liu C; Zhang X; Wang W; Li B; Liu J; Liu Y; Sun H; Zhang D; Hou Y; Zhang H; Yang B
    ACS Appl Mater Interfaces; 2018 Jun; 10(24):20342-20355. PubMed ID: 29878757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mace-Like Plasmonic Au-Pd Heterostructures Boost Near-Infrared Photoimmunotherapy.
    Feng Y; Ning X; Wang J; Wen Z; Cao F; You Q; Zou J; Zhou X; Sun T; Cao J; Chen X
    Adv Sci (Weinh); 2023 Feb; 10(6):e2204842. PubMed ID: 36599677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational Design of a Robust Antibody-like Small-Molecule Inhibitor Nanoplatform for Enhanced Photoimmunotherapy.
    Shang Q; Zhou S; Jiang Y; Wang D; Wang J; Song A; Luan Y
    ACS Appl Mater Interfaces; 2020 Sep; 12(36):40085-40093. PubMed ID: 32791825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy.
    Zhang L; Zhao X; Niu Y; Ma X; Yuan W; Ma J
    J Extracell Vesicles; 2023 Nov; 12(11):e12379. PubMed ID: 37974395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
    Nagaya T; Nakamura Y; Sato K; Harada T; Choyke PL; Hodge JW; Schlom J; Kobayashi H
    Oncotarget; 2017 Jan; 8(5):8807-8817. PubMed ID: 27716622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical Tumor-Derived Photothermal Nanovaccine for Personalized Cancer Therapy and Prevention.
    Li T; Chen G; Xiao Z; Li B; Zhong H; Lin M; Cai Y; Huang J; Xie X; Shuai X
    Nano Lett; 2022 Apr; 22(7):3095-3103. PubMed ID: 35357839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Self-Delivery Nanodrug Simultaneously Inhibits COX-2/PGE
    Lai JM; Chen PL; Shi QY; Xie YQ; Jiaerheng G; Liu LH
    Adv Healthc Mater; 2024 Aug; 13(20):e2400367. PubMed ID: 38704750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-targeted photoimmunotherapy induces antitumor immunity and can be augmented by anti-PD-1 therapy for durable anticancer responses in an immunologically active murine tumor model.
    Hsu MA; Okamura SM; De Magalhaes Filho CD; Bergeron DM; Rodriguez A; West M; Yadav D; Heim R; Fong JJ; Garcia-Guzman M
    Cancer Immunol Immunother; 2023 Jan; 72(1):151-168. PubMed ID: 35776159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors.
    Choo YW; Kang M; Kim HY; Han J; Kang S; Lee JR; Jeong GJ; Kwon SP; Song SY; Go S; Jung M; Hong J; Kim BS
    ACS Nano; 2018 Sep; 12(9):8977-8993. PubMed ID: 30133260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.